PubMed

Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept.

Crnkic M, Månsson B, Larsson L, Geborek P, Heinegård D, Saxne T.

Arthritis Res Ther. 2003;5(4):R181-5. Epub 2003 Apr 29.PMID: 12823852 [PubMed - indexed for MEDLINE]Related articlesFree article

[Evidence of cartilaginous benefit of treatment with infliximab in rheumatoid arthritis using measurement of serum COMP]

Yamamoto M, Takahashi H, Ohara M, Suzuki C, Naishiro Y, Yamamoto H, Shinomura Y, Imai K.

Nihon Rinsho Meneki Gakkai Kaishi. 2007 Feb;30(1):41-7. Japanese. PMID: 17332704 [PubMed - indexed for MEDLINE]Related articlesFree article

Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study.

Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, Weisman M, Wallace DJ, Crues J, Khanna D, Eckel G, Yeilding N, Callegari P, Visvanathan S, Rojas J, Hegedus R, George L, Mamun K, Gilmer K, Troum O.

Ann Rheum Dis. 2007 Jul;66(7):893-9. Epub 2007 Apr 5.PMID: 17412737 [PubMed - indexed for MEDLINE]Related articlesFree article

C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.

Buch MH, Seto Y, Bingham SJ, Bejarano V, Bryer D, White J, Emery P.

Arthritis Rheum. 2005 Jan;52(1):42-8.PMID: 15641046 [PubMed - indexed for MEDLINE]Related articlesFree article

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.PMID: 17049139 [PubMed - indexed for MEDLINE]Related articlesFree article

Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis.

Morozzi G, Fabbroni M, Bellisai F, Cucini S, Simpatico A, Galeazzi M.

Clin Rheumatol. 2007 Aug;26(8):1335-8. Epub 2007 Feb 7.PMID: 17285224 [PubMed - indexed for MEDLINE]Related articles

[Cartilage oligomeric matrix protein (COMP): the role of a non-collagen cartilage matrix protein as a marker of disease activity and joint destruction in patients with rheumatoid arthritis and osteoarthritis]

Marti C, Neidhart M, Gerber T, Hauser N, Michel BA, Häuselmann HJ.

Z Rheumatol. 1999 Apr;58(2):79-87. German. PMID: 10408068 [PubMed - indexed for MEDLINE]Related articles

The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.

Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN, Tsai CY, Chou CT.

Ann Rheum Dis. 2006 Jan;65(1):35-9. Epub 2005 Jun 23.PMID: 15975966 [PubMed - indexed for MEDLINE]Related articlesFree article

Serum levels of cartilage oligomeric matrix protein. A predicting factor and a valuable parameter for disease management in rheumatoid arthritis.

Skoumal M, Kolarz G, Klingler A.

Scand J Rheumatol. 2003;32(3):156-61.PMID: 12892252 [PubMed - indexed for MEDLINE]Related articles

Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.

Maksymowych WP, Poole AR, Hiebert L, Webb A, Ionescu M, Lobanok T, King L, Davis JC Jr.

J Rheumatol. 2005 Oct;32(10):1911-7.PMID: 16206346 [PubMed - indexed for MEDLINE]Related articles

Serum levels of cartilage oligomeric matrix protein (COMP): a rapid decrease in patients with active rheumatoid arthritis undergoing intravenous steroid treatment.

Skoumal M, Haberhauer G, Feyertag J, Kittl EM, Bauer K, Dunky A.

Rheumatol Int. 2006 Sep;26(11):1001-4. Epub 2006 Feb 17.PMID: 16485108 [PubMed - indexed for MEDLINE]Related articles

[Etanercept in rheumatoid arthritis patients with a poor therapeutic response to infliximab]

Sanmartí R, Gómez-Puerta JA, Rodríguez-Cros JR, Albaladejo C, Muñoz-Gómez J, Cañete JD.

Med Clin (Barc). 2004 Mar 13;122(9):321-4. Spanish. PMID: 15033049 [PubMed - indexed for MEDLINE]Related articles

Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

Geborek P, Crnkic M, Petersson IF, Saxne T; South Swedish Arthritis Treatment Group.

Ann Rheum Dis. 2002 Sep;61(9):793-8.PMID: 12176803 [PubMed - indexed for MEDLINE]Related articlesFree article

Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.

Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE; ATTRACT Study Group.

Arthritis Rheum. 2005 Apr;52(4):1020-30.PMID: 15818697 [PubMed - indexed for MEDLINE]Related articlesFree article

Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis.

Andersson ML, Petersson IF, Karlsson KE, Jonsson EN, Månsson B, Heinegård D, Saxne T.

Ann Rheum Dis. 2006 Nov;65(11):1490-4. Epub 2006 May 17.PMID: 16707535 [PubMed - indexed for MEDLINE]Related articlesFree article

Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.

Iannone F, Trotta F, Montecucco C, Giacomelli R, Galeazzi M, Matucci-Cerinic M, Ferri C, Cutolo M, Maria Bambara L, Triolo G, Ferraccioli G, Valentini G, Lapadula G; GISEA (Gruppo Italiano per lo Studio delle Early Arthritis).

Ann Rheum Dis. 2007 Feb;66(2):249-52. Epub 2006 Jul 12. Erratum in: Ann Rheum Dis. 2007 Jun;66(6):847. Monteccuco, Carlomaurizio [corrected to Montecucco, Carlomaurizio]. PMID: 16837489 [PubMed - indexed for MEDLINE]Related articlesFree article

[Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis]

Wallenius M, Rødevand E, Skomsvoll JF.

Tidsskr Nor Laegeforen. 2005 Jun 16;125(12):1664-6. Norwegian. PMID: 15976836 [PubMed - indexed for MEDLINE]Related articlesFree article

Short-term infliximab therapy improves symptoms of psoriatic arthritis and decreases concentrations of cartilage oligomeric matrix protein.

Cauza E, Hanusch-Enserer U, Frischmuth K, Fabian B, Dunky A, Kostner K.

J Clin Pharm Ther. 2006 Apr;31(2):149-52.PMID: 16635048 [PubMed - indexed for MEDLINE]Related articles

Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Hyrich KL, Symmons DP, Watson KD, Silman AJ; British Society for Rheumatology Biologics Register.

Arthritis Rheum. 2006 Jun;54(6):1786-94.PMID: 16736520 [PubMed - indexed for MEDLINE]Related articlesFree article

Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.

Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L, Ulfgren AK.

Rheumatology (Oxford). 2002 May;41(5):484-9.PMID: 12011369 [PubMed - indexed for MEDLINE]Related articlesFree article